O	0	1	A
O	2	12	randomized
O	13	18	phase
O	19	22	III
O	23	28	study
O	29	39	evaluating
B-intervention	40	49	pegylated
I-intervention	50	59	liposomal
I-intervention	60	71	doxorubicin
O	72	78	versus
B-control	79	91	capecitabine
O	92	94	as
O	95	100	first
O	100	101	-
O	101	105	line
O	106	113	therapy
O	114	117	for
O	118	128	metastatic
O	129	135	breast
O	136	142	cancer
O	142	143	:
O	144	151	results
O	152	154	of
O	155	158	the
O	159	166	PELICAN
O	167	172	study
O	172	173	.

O	174	177	The
O	178	185	PELICAN
O	186	191	trial
O	192	201	evaluates
O	202	205	for
O	206	209	the
O	210	215	first
O	216	220	time
O	221	229	efficacy
O	230	233	and
O	234	240	safety
O	241	243	of
O	244	253	pegylated
O	254	263	liposomal
O	264	275	doxorubicin
O	276	277	(
O	277	280	PLD
O	280	281	)
O	282	288	versus
O	289	301	capecitabine
O	302	304	as
O	305	310	first
O	310	311	-
O	311	315	line
O	316	325	treatment
O	326	328	of
O	329	339	metastatic
O	340	346	breast
O	347	353	cancer
O	354	355	(
O	355	358	MBC
O	358	359	)
O	359	360	.

O	361	365	This
O	366	376	randomized
O	376	377	,
O	378	383	phase
O	384	387	III
O	387	388	,
O	389	393	open
O	393	394	-
O	394	399	label
O	399	400	,
O	401	412	multicenter
O	413	418	trial
O	419	427	enrolled
B-eligibility	428	433	first
I-eligibility	433	434	-
I-eligibility	434	438	line
I-eligibility	439	442	MBC
I-eligibility	443	451	patients
I-eligibility	452	455	who
I-eligibility	456	460	were
I-eligibility	461	471	ineligible
I-eligibility	472	475	for
I-eligibility	476	485	endocrine
I-eligibility	486	488	or
I-eligibility	489	500	trastuzumab
I-eligibility	501	508	therapy
O	508	509	.

O	510	520	Cumulative
O	521	529	adjuvant
O	530	544	anthracyclines
O	545	547	of
O	548	551	360
O	552	554	mg
O	554	555	/
O	555	557	m2
O	558	569	doxorubicin
O	570	572	or
O	573	583	equivalent
O	584	588	were
O	589	596	allowed
O	596	597	.

O	598	602	Left
O	603	614	ventricular
O	615	623	ejection
O	624	632	fraction
O	633	635	of
O	636	637	>
O	637	639	50
O	640	641	%
O	642	645	was
O	646	654	required
O	654	655	.

O	656	664	Patients
O	665	673	received
O	674	677	PLD
O	678	680	50
O	681	683	mg
O	683	684	/
O	684	686	m2
O	687	692	every
O	693	695	28
O	696	700	days
O	701	703	or
O	704	716	capecitabine
O	717	721	1250
O	722	724	mg
O	724	725	/
O	725	727	m2
O	728	733	twice
O	734	739	daily
O	740	743	for
O	744	746	14
O	747	751	days
O	752	757	every
O	758	760	21
O	761	765	days
O	765	766	.

O	767	770	The
O	771	778	primary
O	779	787	endpoint
O	788	791	was
B-outcome-Measure	792	796	time
I-outcome-Measure	796	797	-
I-outcome-Measure	797	799	to
I-outcome-Measure	799	800	-
I-outcome-Measure	800	807	disease
I-outcome-Measure	808	819	progression
I-outcome-Measure	820	821	(
I-outcome-Measure	821	824	TTP
I-outcome-Measure	824	825	)
O	825	826	.

B-total-participants	827	830	210
O	831	839	patients
O	840	844	were
O	845	855	randomized
O	856	857	(
O	857	858	n
O	859	860	=
B-intervention-participants	861	864	105
O	864	865	,
O	866	869	PLD
O	870	873	and
O	874	875	n
O	876	877	=
B-control-participants	878	881	105
O	881	882	,
O	883	895	capecitabine
O	895	896	)
O	896	897	.

B-outcome	898	906	Adjuvant
I-outcome	907	921	anthracyclines
O	922	926	were
O	927	932	given
O	933	935	to
B-iv-bin-percent	936	938	37
I-iv-bin-percent	939	940	%
O	941	942	(
O	942	945	PLD
O	945	946	)
O	947	950	and
B-cv-bin-percent	951	953	36
I-cv-bin-percent	954	955	%
O	956	957	(
O	957	969	capecitabine
O	969	970	)
O	971	973	of
O	974	982	patients
O	982	983	.

O	984	986	No
O	987	998	significant
O	999	1009	difference
O	1010	1013	was
O	1014	1022	observed
O	1023	1025	in
B-outcome	1026	1029	TTP
O	1030	1031	[
O	1031	1033	HR
O	1034	1035	=
O	1036	1037	1
O	1037	1038	.
O	1038	1040	21
O	1041	1042	(
O	1042	1044	95
O	1045	1046	%
O	1047	1057	confidence
O	1058	1066	interval
O	1066	1067	,
O	1068	1069	0
O	1069	1070	.
O	1070	1073	838
O	1073	1074	-
O	1074	1075	1
O	1075	1076	.
O	1076	1079	750
O	1079	1080	)
O	1080	1081	]
O	1081	1082	.

B-outcome	1083	1089	Median
I-outcome	1090	1093	TTP
O	1094	1097	was
B-iv-cont-median	1098	1099	6
I-iv-cont-median	1099	1100	.
I-iv-cont-median	1100	1101	0
I-iv-cont-median	1102	1108	months
O	1109	1112	for
O	1113	1117	both
O	1118	1121	PLD
O	1122	1125	and
O	1126	1138	capecitabine
O	1138	1139	.

O	1140	1149	Comparing
O	1150	1158	patients
O	1159	1163	with
O	1164	1166	or
O	1167	1174	without
O	1175	1180	prior
O	1181	1195	anthracyclines
O	1195	1196	,
O	1197	1199	no
O	1200	1211	significant
O	1212	1222	difference
O	1223	1225	in
B-outcome	1226	1229	TTP
O	1230	1233	was
O	1234	1242	observed
O	1243	1245	in
O	1246	1249	the
O	1250	1253	PLD
O	1254	1257	arm
O	1258	1259	(
O	1259	1262	log
O	1262	1263	-
O	1263	1267	rank
O	1268	1269	P
O	1270	1271	=
O	1272	1273	0
O	1273	1274	.
O	1274	1276	64
O	1276	1277	)
O	1277	1278	.

O	1279	1282	For
O	1283	1286	PLD
O	1287	1293	versus
O	1294	1306	capecitabine
O	1306	1307	,
O	1308	1320	respectively
O	1320	1321	,
B-outcome	1322	1329	overall
I-outcome	1330	1338	survival
O	1339	1340	(
O	1340	1346	median
O	1346	1347	,
B-iv-cont-median	1348	1350	23
I-iv-cont-median	1350	1351	.
I-iv-cont-median	1351	1352	3
I-iv-cont-median	1353	1359	months
O	1360	1362	vs
O	1362	1363	.
B-cv-cont-median	1364	1366	26
I-cv-cont-median	1366	1367	.
I-cv-cont-median	1367	1368	8
I-cv-cont-median	1369	1375	months
O	1375	1376	)
O	1377	1380	and
B-outcome	1381	1385	time
I-outcome	1385	1386	-
I-outcome	1386	1388	to
I-outcome	1388	1389	-
I-outcome	1389	1398	treatment
I-outcome	1399	1406	failure
O	1407	1408	(
O	1408	1414	median
O	1414	1415	,
B-iv-cont-median	1416	1417	4
I-iv-cont-median	1417	1418	.
I-iv-cont-median	1418	1419	6
I-iv-cont-median	1420	1426	months
O	1427	1429	vs
O	1429	1430	.
B-cv-cont-median	1431	1432	3
I-cv-cont-median	1432	1433	.
I-cv-cont-median	1433	1434	7
I-cv-cont-median	1435	1441	months
O	1441	1442	)
O	1443	1447	were
O	1448	1451	not
O	1452	1465	statistically
O	1466	1479	significantly
O	1480	1489	different
O	1489	1490	.

O	1491	1499	Compared
O	1500	1502	to
O	1503	1506	PLD
O	1506	1507	,
O	1508	1516	patients
O	1517	1519	on
O	1520	1532	capecitabine
O	1533	1544	experienced
O	1545	1549	more
O	1550	1557	serious
O	1558	1565	adverse
O	1566	1572	events
O	1573	1574	(
O	1574	1575	P
O	1576	1577	=
O	1578	1579	0
O	1579	1580	.
O	1580	1583	015
O	1583	1584	)
O	1585	1588	and
O	1589	1593	more
B-outcome	1594	1601	cardiac
I-outcome	1602	1608	events
O	1609	1614	among
O	1615	1623	patients
O	1624	1627	who
O	1628	1631	had
O	1632	1637	prior
O	1638	1651	anthracycline
O	1652	1660	exposure
O	1661	1662	(
B-cv-bin-percent	1662	1664	18
O	1665	1667	vs
O	1667	1668	.
B-iv-bin-percent	1669	1670	8
I-iv-bin-percent	1671	1672	%
O	1672	1673	;
O	1674	1675	P
O	1676	1677	=
O	1678	1679	0
O	1679	1680	.
O	1680	1682	31
O	1682	1683	)
O	1683	1684	.

O	1685	1689	Both
O	1690	1693	PLD
O	1694	1697	and
O	1698	1710	capecitabine
O	1711	1714	are
O	1715	1724	effective
O	1725	1730	first
O	1730	1731	-
O	1731	1735	line
O	1736	1742	agents
O	1743	1746	for
O	1747	1750	MBC
O	1750	1751	.
